European Commission Approves Prolia ® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis

Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The EC approval is based on the positive results of a Phase 3 study that evaluated the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid treatment.1 "We are pleased that today's EC approval provides physicians with a new treatment opti...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news